{"id":"NCT01593787","sponsor":"Novartis Pharmaceuticals","briefTitle":"Safety and Tolerability and Efficacy of LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction","officialTitle":"A Multi-center, Open Label Study for Evaluation of the Safety, Tolerability and Efficacy of 8-week Treatment With LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-05","primaryCompletion":"2013-03","completion":"2013-03","firstPosted":"2012-05-08","resultsPosted":"2015-08-13","lastUpdate":"2015-08-13"},"enrollment":32,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hypertension With Renal Dysfunction"],"interventions":[{"type":"DRUG","name":"LCZ696","otherNames":[]}],"arms":[{"label":"LCZ696 100 mg","type":"EXPERIMENTAL"},{"label":"LCZ696 200 mg","type":"EXPERIMENTAL"},{"label":"LCZ696 400 mg","type":"EXPERIMENTAL"}],"summary":"This study assessed the safety, tolerability, and efficacy of LCZ696 in hypertensive patients with renal dysfunction.","primaryOutcome":{"measure":"Percentage of Participants With Reported Adverse Events (Total Adverse Events, Serious Adverse Events and Death)","timeFrame":"8 weeks","effectByArm":[{"arm":"LCZ696 100 mg","deltaMin":31.3,"sd":null},{"arm":"LCZ696 200 mg","deltaMin":0,"sd":null},{"arm":"LCZ696 400 mg","deltaMin":27.8,"sd":null},{"arm":"Total LCZ696","deltaMin":43.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":6},"locations":{"siteCount":13,"countries":["Japan"]},"refs":{"pmids":["25693859"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":32},"commonTop":["NASOPHARYNGITIS","SUPRAVENTRICULAR EXTRASYSTOLES","DYSPEPSIA","TOOTHACHE","ARTHRALGIA"]}}